Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
RADX Stock Chart & Stats
$4.40
-$0.80(-17.20%)
At close: 4:00 PM EST
$4.40
-$0.80(-17.20%)
Day’s Range― - ―
52-Week Range$3.25 - $50.82
Previous CloseN/A
Volume12.21K
Average Volume (3M)27.90K
Market Cap
$39.87M
Enterprise Value$16.24M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Feb 26, 2026EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding9,268,852
10 Day Avg. Volume15,346
30 Day Avg. Volume27,896
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$19.00Price Target Upside331.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.05
Revenue Forecast (FY)$1.41M
Bulls Say, Bears Say
Bulls Say
Financial BackingRadiopharm raised A$35M in an institutional placement which funds the company into CY27 and supports ongoing clinical trials.
Innovative PipelineThe license agreement with Starpharma demonstrates that Radiopharm Theranostics is committed to maintaining an innovative and novel pipeline to ensure it remains competitive.
Strategic InvestmentLantheus, a major player in radiopharmaceuticals, invested further in Radiopharm, indicating confidence in its potential pipeline.
Bears Say
Financial LossRadiopharm Theranostics reported a net loss of ($25.3M), or (A$38.3M), which indicates financial challenges.
Financial ObligationsRadiopharm is to pay up to A$89M in development, regulatory, and commercial milestones, plus a royalty on sales, which could be a significant financial obligation.
Increased ExpensesExpense estimates for FY26 and FY27 have been increased due to ongoing expenses and development programs.
Radiopharm Theranostics Limited Sponsored ADR News
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.25 and its highest was $50.82 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $39.87M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2026 which is in 102 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Sep 16, 2025. The company reported -$1.952 earnings per share for the quarter, beating the consensus estimate of -$1.961 by $0.009.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.49.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 9,268,852 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$1.952 in its last earnings report, beating expectations of -$1.961. Following the earnings report the stock price went up 1.429%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (331.82% Upside)
$19.00 (331.82% Upside)
Blogger Sentiment
Bullish
RADX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.56%
12-Months-Change
Fundamentals
Return on Equity
-98.81%
Trailing 12-Months
Asset Growth
17.81%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
RADX Stock 12 Month Forecast
Average Price Target
$19.00
▲(331.82% Upside)
Technical Analysis
Serina Therapeutics
―
Celularity
―
Barinthus Biotherapeutics
―
Acrivon Therapeutics, Inc.
―
Telomir Pharmaceuticals, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
3.39% Other Institutional Investors
96.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---